Therapy of human ovarian cancer by transfection with the murine interferon β gene: Role of macrophage-inducible nitric oxide synthase

Human Gene Therapy

Volumn 9, Issue 18, 1998, Pages 2699-2708

  Xu, Lei ^a   Xie, Keping ^a   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; NEOMYCIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DNA TRANSFECTION; ENZYME INDUCTION; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PERITONEAL CAVITY;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0032506770     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1998.9.18-2699     Document Type: Article

References (50)

1. BARON, S., and DIANZANI, F. (1994). The interferons: A biological system with therapeutic potential in viral infections. Antiviral Res. 24, 97-110.
2. BRZOSKA, J., and OBERT, H.-J. (1990). Immunomodulating effects of interferons: conclusions for therapy. In Genital Papillomavirus Infections. G. Gross, S. Jablonska, H. Pfister, and H. E. Stegner, eds. (Springer-Verlag, Berlin) pp. 379-391.
3. BUICK, R.N., PULLANO, R., and TRENT, J.M. (1985). Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res. 45, 3668-3676.
4. BULBUL, M.A., HUBEN, R.P., and MURPHY, G.P. (1986). Interferon-β treatment of metastatic prostate cancer. J. Surg. Oncol. 33, 231-233.
5. DING, A., NATHAN, C., and STUEHR, D.J. (1988). Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: Comparison of activating cytokines and evidence for independent production. J. Immunol. 141, 2407-2412.
6. DINNEY, C.P.N., BIELENBERG, D.R., REICH, R., EVE, B.Y., PERROTTE, P., BUCANA, C.D., and FIDLER, I.J. (1998). Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 58, 808-814.
7. DONG, Z., QI, X., and FIDLER, I.J. (1993a). Tyrosine phosphorylation of mitogen-activated protein kinases is necessary for activation of murine macrophages by natural and synthetic bacterial products. J. Exp. Med. 177, 1071-1077.
8. DONG, Z., QI, X, XIE, K., and FIDLER, I.J. (1993b). Protein tyrosine kinase inhibitors decrease induction of nitric oxide synthase activity in LPS-responsive and LPS-nonresponsive murine macrophages. J. Immunol. 151, 2717-2724.
9. DONG, Z., JUANG, S.H., KUMAR, R., EUE, I., XIE, K., BIELENBERG, D., LU, W., BUCANA, C.D., YANG, X., and FIDLER, I.J. (1998). Suppression of tumorigenicity and metastass in murine UV-2237 fibrosarcoma cells by infection with a retroviral vector harboring the interferon-beta gene. Cancer Immunol. Immunother. 46, 137-146.
10. DUNCAN, M.R., and BERMAN, B. (1989). Differential regulation of glycosaminoglycan, fibronectin, and collagenase production in cultured human dermal fibroblasts by interferon-α, -β, and -γ. Arch. Dermatol. Res. 281, 11-18.
11. DVORAK, H., and GRESSER, I. (1989). Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J. Natl. Cancer Inst. 81, 497-502.
12. EINHORN, S., and GRANDER, D. (1996). Why do so many cancer patients fail to respond to interferon therapy? J. Interferon Cytokine Res. 16, 275-281.
13. FABRA, A., NAKAJIMA, M., BUANCA, C.D., and FIDLER, I.J. (1992). Modulation of the invasive phenotype of human colon carcinoma cells by organ-specific fibroblasts of nude mice. Differentiation 52, 101-110.
14. FIDLER, I.J., and ELLIS, L.M. (1994). The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79, 185-188.
15. FOLKMAN, J. (1991). Angiogenesis. J. Biol. Chem. 267, 10931-10934.
16. FOLKMAN, J. (1992). The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3, 65-71.
17. FRASCI, G., TORTORIELLO, A., FACCHINI, G., CON FORTI, S., PERSICO, G., MASTRANTONIO, P., CARDONE, A., and IAFFAIOLI, R.V. (1994). Carboplatin and α-2b interferon intraperitoneal combination as first line treatment of minimal residual ovarian cancer. A pilot study. Eur. J. Cancer 30A, 946-950.
18. GOHJI, K., FIDLER, I.J., TSAN, R., RADINSKY, R., VON ESCHENBACH, A.C., TSURUO, T., and NAKAJIMA, M. (1994). Human recombinant interferons beta and gamma decrease gelatinase production and invasion by human KG-2 renal carcinoma cells. Int. J. Cancer 58, 380-384.
19. GORLACH, A., HERTER, P., HENTSCHEL, H., FROSCH, P.J., and ACKER, H. (1994). Effects of mIFN-β and rIFN-γ on growth and morphology of two human melanoma cell lines: Comparison between two- and three-dimensional culture. Int. J. Cancer 56, 249-256.
20. GRANDER, D., XU, B., and EINHORN, S. (1983). Cytotoxic effect of interferon on primary maligant tumor cells. Studies in various malignancies. Eur. J. Cancer 29A, 1940-1943.
21. GUTTERMAN, J. (1994). Cytokine therapeutics: Lessons from interferon-α. Proc. Natl. Acad. Sci. U.S.A. 91, 1198-1205.
22. HERTZOG, P.J., HWANG, S.Y., and KOLA, I. (1994). Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol. Reprod. Dev. 39, 226-232.
23. ISAACS, A., and LINDENMANN, J. (1957). Virus interference. I. The interferons. Proc. R. Soc. Ser. B 147, 258-263.
24. JOHNS, T.G., MACKAY, I.R., CALLISTER, K.A., HERTZOG, P.J., DEVENISH, R.J., and LINNANE, A.W. (1992). Antiproliferative potencies of interferons on melanoma cell lines and xenografts: Higher efficacy of interferon-β. J. Natl. Cancer Inst. 80, 1185-1189.
25. KITADAI, Y., RADINSKY, R., BUCANA, C.D., TAKAHASHI, Y., XIE, K., and FIDLER, I.J. (1996). Regulation of CEA expression in human colon carcinoma cells by the organ microenvironment. Am. J. Pathol. 149, 1157-1166.
26. KROWN, S.E. (1988). Interferons in malignancy: Biological products or biological response modifiers? J. Natl. Cancer Inst. 80, 306-309.
27. LI, L., PRICE, J.E., FAN, D., ZHANG, R.D., BUCANA, C.D., and FIDLER, I.J. (1989). Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferation capacity at specific metastatic sites. J. Natl. Cancer Inst. 81, 1406-1412.
28. LOKSHIN, A., MAYOTTE, J.E., and LEVITT, M.L. (1995). Mechanism of interferon-β-induced squamous differentiation and programmed cell death in human non-small cell lung cancer cell lines. J. Natl. Cancer Inst. 87, 206-210.
29. MOORE, D.H., VALEA, F., WALTON, L.A., SOPER, J., CLARKE-PEARSON, D., and FOWER, W.C., JR. (1995). A phase I study of intraperitoneal interferon-α2b and intravenous cis-platinum plus cyclophosphamide chemotherapy in patients with untreated stage ITI epithelial ovarian cancer: A gynecologic oncology group pilot study. Gynecol. Oncol. 59, 267-272.
30. NATHAN, C. (1992). Nitric oxide as a secretory product of mammalian cells. FASEB J. 6, 3051-3064.
31. OLIVEIRA, I.C., SCIAVOLINO, P.J., LEE, T.H., and VILCEK, J. (1992). Downregulation of interleukin-8 gene expression in human fibroblasts: Unique mechanism of transcriptional inhibition by interferon. Proc. Natl. Acad. Sci. U.S.A. 89, 9049-9055.
32. ORTALDO, J.R., and HERBERMAN, R.B. (1986). Augmentation of natural killer activity. In Immunobiology of Natural Killer Cells, Vol. II. E. Lotzova, ed. (CRC Press, Boca Raton, FL) pp. 145-171.
33. OZOLS, R.F., SCHWARTZ, P.E., and EIFEL, P.J. (1997). Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In Principles and Practice of Oncology, 5th Ed. V.T. DeVita, S. Hellman, and S.A. Rosenberg, eds. (Lippincott-Raven, New York) pp. 1502-1539.
34. RICHES, D.W., and UNDERWOOD, G.A. (1991). Expression of interferon-β during the triggering phase of macrophage cytocidal activation. Evidence for an autocrine/paracrine role in the regulation of this state. J. Biol. Chem. 266, 24785-24794.
35. SALMON, P., LE COTONNEC, J.Y., GALAZKA, A., ABDULAHAD, A., and DARRAGH, A. (1996). Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J. Interferon Cytokine Res. 16, 759-764.
36. SCHILLER, J.H., STORER, B., BITTNER, G., WILSON, J.K., and BORDEN, E.C. (1988). Phase II trial of a combination of interferon-β ser and interferon-γ in patients with advanced malignant melanoma. J. Interferon Res. 8, 581-589.
37. SICA, G., FABBRONI, L., CASTAGNETTA, L., CACCIATORE, J., and PAVONE-MACULUSO, M. (1989). Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol. Res. 17, 111-115.
38. SICA, G., FABBRONI, L., DELL'ACQUA, G., IACOPINO, F., MARCHETTI, P., CACCIATORE, M., and PAVONE-MACULUSO, M. (1991). Natural beta-interferon and androgen receptors in prostatic cancer cells. Urol. Int. 46, 159-164.
39. SINGH, R.K., GUTMAN, M., BUCANA, C.D., SANCHEZ, R., LLANSA, N., and FIDLER, I.J. (1995). Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. U.S.A. 92, 4562-4569.
40. TALPAZ, M., ROSENBLOOM, M., KURZROCK, R., REUBEN, J., KANTARJIAN, H., and GUTTERMAN, J. (1987). Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia - a pilot study. Am. J. Hematol. 24, 341-350.
41. THOMAS, H., and BALKWILL, F.R. (1991). Effects of interferons and other cytokines on tumors in animals: A review. Pharmacol. Ther. 52, 307-314.
42. VAN DAMME, J., and OPDENAKKER, G. (1990). Interaction of interferons with skin reactive cytokines: From interleukin-1 to interleukin-8. J. Invest. Dermatol. 95, 906-912.
43. XIE, K., and FIDLER, I.J. (1998). Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev. 17, 55-75.
44. XIE, K., HUANG, S., DONG, Z., GUTMAN, M., and FIDLER, I.J. (1995). Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Cancer Res. 55, 2123-3131.
45. XIE, K., DONG, Z., and FIDLER, I.J. (1996). Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J. Leukocyte Biol. 59, 797-803.
46. XIE, K., HUANG, S., DONG, Z., JUANG, S.-H., WANG, Y., and FIDLER, I.J. (1997a). Destruction of bystander cells by tumor cells transfected with inducible nitric oxide synthase gene. J. Natl. Cancer Inst. 89, 421-427.
47. XIE, K., BIELENBERG, D., HUANG, S., SALAS, T., JUANG, S.-H., DONG, Z., and FIDLER, I.J. (1997b). Abrogation of tumorigenicity and metastasis of murine and human tumor cells by transfection with the murine interferon-β gene: Possible role of nitric oxide. Clin. Cancer Res. 3, 2283-2294.
48. YONEDA, J., KUNIYASU, H., CRISPENS, M.A., PRICE, J.E., BUCANA, C.D., and FIDLER, I.J. (1998). Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl. Cancer Inst. 90, 447-454.
49. YU, D., WOLF, J.K., SCANLON, M., PRICE, J.E., and HUANG, M,-C. (1993). Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 53, 891-898.
50. ZHANG, X., ALLEY, E.W., RUSSELL, S.W., and MORRISON, D.C. (1994). Necessity and sufficiency of beta interferon for nitric oxide production in mouse peritoneal macrophages. Infect. Immunol. 62, 33-38.